Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The HIV regimen failed only a few study participants.
This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.
None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.
A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
Merck’s experimental HIV drug proves effective and well tolerated
These medications can now be used by people on stable antiretroviral treatment with undetectable viral load.
This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
An OK would add an indication for the use of these HIV medications among those switching from stable regimens.
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.